Cluster randomised triAl of PSA testing for Prostate cancer

Conditions

Prostate cancer Cancer Malignant neoplasm of prostate

Richard M. Martin, Emma L. Turner, Grace Young, Chris Metcalfe, Eleanor Walsh et al. (61 authors)

JAMA2024-04-0676 citations

10.1001/jama.2024.4011

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality

Richard M. Martin, Jenny Donovan, Emma L. Turner, Chris Metcalfe, Grace Young et al. (27 authors)

JAMA2018-03-06403 citations

10.1001/jama.2018.0154

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study

Grace Young, Sean Harrison, Emma L. Turner, Eleanor Walsh, Steven Oliver et al. (13 authors)

BMJ Open2017-10-0149 citations

10.1136/bmjopen-2017-017729

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial

Eleanor Walsh, Emma L. Turner, J. Athene Lane, Jenny Donovan, David E. Neal et al. (10 authors)

Trials2016-10-137 citations

10.1186/s13063-016-1624-6

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)

Joanna Thorn, Emma L. Turner, Luke Hounsome, Eleanor Walsh, Liz Down et al. (11 authors)

BMJ Open2016-04-0131 citations

10.1136/bmjopen-2016-011063

Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).

Williams NJ, Hill EM, Ng SY, Martin RM, Metcalfe C, Donovan JL, Evans S, Hughes LJ, Davies CF, Hamdy FC, Neal DE, Turner EL, CAP Cause of Death Committee.

2015-01-239 citations

10.1186/1471-2288-15-6

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.

Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL.

2010-11-0198 citations

10.1016/j.ejca.2010.09.016

Interventions

Current interventions as of 06/08/2014: General practices are randomised to participate in The ProtecT study (see ISRCTN20141297) or the control arm of the trial. In the ProtecT arm of the trial men a

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Current inclusion criteria as of 06/08/2014: All men aged 50 - 69 years from 573 GP practices in eight UK centres (Sheffield, Newcastle, Bristol, Birmingham, Cardiff, Leeds, Cambridge, Leicester). An additional centre, Edinburgh, where routine data on cause of death did not undergo validation, will be included in a secondary analysis. Previous inclusion criteria: All men aged 50 - 69 years from approximately 400 GP practices in nine UK centres (Sheffield, Newcastle, Bristol, Birmingham, Cardiff, Edinburgh, Leeds, Cambridge, Leicester)

Exclusion criteria

Exclusion criteria: Current exclusion criteria as of 06/08/2014: Inclusion criteria not met. Men identified as already having a prostate cancer diagnosis. Previous exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Current primary outcome measure as of 04/02/2021: Prostate cancer mortality at 15 years See statistical analysis plan for further details: http://hdl.handle.net/1983/97a58ee2-e559-49e3-9029-954bd5dd5bd9 DOI: 10.17605/OSF.IO/7Y3G6 _____ Previous primary outcome measure: Prostate cancer mortality at 10 years Added 06/08/2014: See statistical analysis plan for further details: http://hdl.handle.net/1983/6d41509f-ab93-4f96-9869-c320acbc4ae1	—

Measure

Time frame

Current primary outcome measure as of 04/02/2021: Prostate cancer mortality at 15 years See statistical analysis plan for further details: http://hdl.handle.net/1983/97a58ee2-e559-49e3-9029-954bd5dd5bd9 DOI: 10.17605/OSF.IO/7Y3G6 _____ Previous primary outcome measure: Prostate cancer mortality at 10 years Added 06/08/2014: See statistical analysis plan for further details: http://hdl.handle.net/1983/6d41509f-ab93-4f96-9869-c320acbc4ae1

—

Secondary

Measure	Time frame
Current secondary outcome measures as of 04/02/2021: Measured at 5 and 10, 15 and 20 years: 1. All-cause mortality 2. Disease status and staging 3. Cost-effectiveness: The projected lifetime effectiveness and cost-effectiveness of a range of UK-focused screening options, incorporating parameter estimates computed from CAP and ProtecT data to create a UK-specific decision analytic model 4. Health-related quality of life 5. Age-specific lead-time and over-diagnosis rates (utilising observed trial data) _____ Previous secondary outcome measures as of 06/08/2014: Measured at 5 and 10, 15 and 20 years: 1. All-cause mortality 2. Disease status and staging 3. Cost-effectiveness 4. Health-related quality of life _____ Previous secondary outcome measures: Measured at 5 and 10 years: 1. All-cause mortality 2. Disease status and staging 3. Cost-effectiveness 4. Health-related quality of life	—

Measure

Time frame

Current secondary outcome measures as of 04/02/2021: Measured at 5 and 10, 15 and 20 years: 1. All-cause mortality 2. Disease status and staging 3. Cost-effectiveness: The projected lifetime effectiveness and cost-effectiveness of a range of UK-focused screening options, incorporating parameter estimates computed from CAP and ProtecT data to create a UK-specific decision analytic model 4. Health-related quality of life 5. Age-specific lead-time and over-diagnosis rates (utilising observed trial data) _____ Previous secondary outcome measures as of 06/08/2014: Measured at 5 and 10, 15 and 20 years: 1. All-cause mortality 2. Disease status and staging 3. Cost-effectiveness 4. Health-related quality of life _____ Previous secondary outcome measures: Measured at 5 and 10 years: 1. All-cause mortality 2. Disease status and staging 3. Cost-effectiveness 4. Health-related quality of life

—

Countries

England, United Kingdom

Outcome results

None listed